Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 7, 2005, Pages 2634-2641

  Shearer, Jeffry D ^a   Siemann, Linda ^b   Gerkovich, Mary ^b   House, Robert V ^a  

^a DKC LLC   (United States)

^b MIDWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINIA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; LETHALITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL; TREATMENT OUTCOME; VACCINIA; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICE, SCID; NEUTRALIZATION TESTS; TAIL; VACCINIA; VACCINIA VIRUS;

EID: 21444459872     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.7.2634-2641.2005     Document Type: Article

References (28)

1. Baker, R. O., M. Bray, and J. W. Muggins. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 57:13-23.
2. Belyakov, I. M., P. Earl, A. Dzutsev, V. A. Kuznetsov, M. Lemon, L. S. Wyatt, J. T. Snyder, J. D. Ahlers, G. Franchini, B. Moss, and J. A. Berzofsky. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100:9458-9463.
3. Boyle, J. J., R. F. Haff, and R. C. Stewart. 1966. Evaluation of antiviral compounds by suppression of tail lesions in vaccinia-infected mice. Antimicrob. Agents Chemother. 6:536-539.
4. Bray, M. 2003. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res. 58:101-114.
5. Bray, M., and M. E. Wright. 2003. Progressive vaccinia. Clin. Infect. Dis. 36:766-774.
6. Centers for Disease Control and Prevention. 2003. Update: cardiac and other adverse events following civilian smallpox vaccination-United States, 2003. Morb. Mortal. Wkly. Rep. 52:639-642.
7. De Clercq, E., and P. De Somer. 1968. Effect of interferon, polyacrylin acid, and polymethacrylic acid on tail lesions on mice infected with vaccinia virus. Appl. Microbiol. 16:1314-1319.
8. De Clercq, E., M. Luczak, D. Shugar, P. F. Torrence, J. A. Waters, and B. Witkop. 1976. Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc. Soc. Exp. Biol. Med. 151:487-490.
9. Edghill-Smith, Y., D. Venzon, T. Karpova, J. McNally, J. Nacsa, W. P. Tsai, E. Tryniszewska, M. Moniuszko, J. Manischewitz, L. R. King, S. J. Snodgrass, J. Parrish, P. Markham, M. Sowers, D. Martin, M. G. Lewis, J. A. Berzofsky, I. M. Belyakov, B. Moss, J. Tartaglia, M. Bray, V. Hirsch, H. Golding, and G. Franchini. 2003. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J. Infect. Dis. 188:1181-1191.
10. Goldsmith, J. C., N. Eller, M. Mikolajczyk, J. Manischewitz, H. Golding, and D. E. Scott. 2004. Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia. Vox Sanguinis 86:125-129.
11. Goldstein, J. A., J. M. Neff, J. M. Lane, and J. P. Koplan. 1975. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 55:342-347.
12. Hopkins, R. J., W. Kramer, W. Blackwelder, M. Ashtekar, L. Hague, S. D. Winker-La Roche, G. Berezuk, D. Smith, and P. T. Leese. 2004. Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers. Clin. Infect. Dis. 39:759-766.
13. Institute of Medicine. 1999. Assessment of future scientific needs for live variola virus. National Academic Press, Washington, D.C.
14. Kempe, C. H., T. Berge, and B. England. 1956. Hyperimmune vaccinial gamma globulin: source, evaluation and use in prophylaxis and therapy. Pediatrics 18:177-188.
15. Lane, J. M., F. L. Ruben, E. Abrutyn, and J. D. Millar. 1970. Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. JAMA 212:441-444.
16. Lane, J. M., F. L. Ruben, J. M. Neff, and J. D. Millar. 1970. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis. 122:303-309.
17. 16a. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academic Press, Washington, D.C.
18. Neff, J. M., J. M. Lane, J. H. Pert, R. Moore, J. D. Millar, and D. A. Henderson. 1967. Complications of smallpox vaccination. I. National survey in the United States, 1963. N. Engl. J. Med. 276:125-132.
19. Neff, J. M., R. H. Levine, J. M. Lane, E. A. Ager, H. Moore, B. J. Rosenstein, J. D. Millar, and D. A. Henderson. 1967. Complications of smallpox vaccination United States 1963. II. Results obtained by four statewide surveys. Pediatrics 39:916-923.
20. Neyts, J., and E. De Clercq. 1993. Efficacy of (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41:242-246.
21. Neyts, J., and E. De Clercq. 2001. Efficacy of 2-amino-7-(1,3-dihydroxy- 2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 45:84-87.
22. Neyts, J., E. Verbeken, and E. De Clercq. 2002. Effect of 5-iodo-2′-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 46:2842-2847.
23. Poole, T. W. 1996. Discovery, development, and history of the SCID mouse. Lab. Animal 25:29-32.
24. Sharp, J. C., and W. B. Fletcher. 1973. Experience of anti-vaccinia immunoglobulin in the United Kingdom. Lancet i:656-659.
25. Smee, D. F., and R. W. Sidwell. 2003. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 57:41-52.
26. Sussman, S., and M. Grossman. 1965. Complications of smallpox vaccination. Effects of vaccinia immune globulin therapy. J. Pediatr. 1965:1168-1173.
27. 't Hart, B. A., S. Amor, and M. Jonker. 2004. Evaluating the validity of animal models for research into therapies for immune-based disorders. Drug Discov. Today 9:517-524.
28. Wharton, M., R. A. Strikas, R. Harpaz, L. D. Rotz, B. Schwartz, C. G. Casey, M. L. Pearson, and L. J. Anderson. 2003. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Morb. Mortal. Wkly. Rep. Recomm. Rep. 52:1-16.